Immunogen (IMGN) Misses Q1 EPS Views; Revenue Light of Consensus

October 28, 2016 7:15 AM EDT
Get Alerts IMGN Hot Sheet
Trade IMGN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.51), $0.13 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.66 million versus the consensus estimate of $21.12 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment